Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

Item
http://www.wikidata.org/entity/Q38001796
Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activityUndetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseBeating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric EpendymomaEvaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in ChinaPharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicityGenotypes Affecting the Pharmacokinetics of Anticancer Drugs.Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice.Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
P2860

Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

Item
http://www.wikidata.org/entity/Q38001796
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evaluation of 5-fluorouracil p ...... ian limited sampling strategy.
@en
type
label
Evaluation of 5-fluorouracil p ...... ian limited sampling strategy.
@en
prefLabel
Evaluation of 5-fluorouracil p ...... ian limited sampling strategy.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P356
P1433
P1476
Evaluation of 5-fluorouracil p ...... ian limited sampling strategy.
@en
P2093
P2860
P2888
P304
P31
P356
10.2165/11595880-000000000-00000
P433
P478
P577
P6179
P698